Acuta Capital Partners, LLC Pmv Pharmaceuticals, Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.17 - $12.95 $236 - $375	-29 Reduced 0.02%	154,471 $1.34 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $17.18 $22,800 - $34,360	2,000 Added 1.31%	154,500 $1.84 Million
Q2 2022 Aug 15, 2022	BUY	$9.23 - $22.43 $156,910 - $381,310	17,000 Added 12.55%	152,500 $2.17 Million
Q1 2022 May 16, 2022	BUY	$14.86 - $23.55 $2.01 Million - $3.19 Million	135,500 New	135,500 $2.82 Million
Q2 2021 Aug 16, 2021	SELL	$28.01 - $36.01 $388,106 - $498,954	-13,856 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$30.66 - $49.5 $35,075 - $56,628	-1,144 Reduced 7.63%	13,856 $456,000
Q4 2020 Feb 16, 2021	BUY	$31.86 - $61.51 $477,900 - $922,650	15,000 New	15,000 $923,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.